Xu, Peng-Peng <br/><br/>
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.  [electronic resource] 

 -  The Lancet. Haematology  Jun 2019 
 - e328-e337 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2352-3026 
<br/><br/><label>Standard No.: </label>10.1016/S2352-3026(19)30051-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anthracyclines--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Cyclophosphamide--administration & dosage<br/>Female<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Neutropenia--etiology<br/>Proportional Hazards Models<br/>Rituximab--administration & dosage<br/>Survival Rate<br/>Treatment Outcome<br/>Vincristine--administration & dosage<br/>Young Adult